Related Experiment Video

Updated: Aug 17, 2026

An Open-Source Normothermic Perfusion System Designed for Research Scientists
11:23

An Open-Source Normothermic Perfusion System Designed for Research Scientists

Published on: July 18, 2025

Derivation of meropenem dosage in patients receiving continuous veno-venous hemofiltration based on pharmacodynamic

Joseph L Kuti1, David P Nicolau

  • 1Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT 06102-5037, USA.

Chemotherapy
|June 30, 2005
PubMed
Abstract

Insights

Meropenem 1,000 mg every 8 hours optimizes antibiotic exposure for patients on continuous veno-venous hemofiltration (CVVH). This dosing ensures bactericidal activity against challenging bacteria like Pseudomonas aeruginosa and Acinetobacter species.

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Nephrology

Background:

  • Antibiotic dosing in continuous veno-venous hemofiltration (CVVH) requires careful consideration of pharmacodynamic targets.
  • Achieving adequate meropenem exposure (time above minimum inhibitory concentration) is crucial for effective treatment.
  • Monte Carlo simulations were used to evaluate meropenem dosing regimens.

Purpose of the Study:

  • To determine optimal meropenem dosing for patients undergoing CVVH.
  • To assess target attainment of meropenem against Pseudomonas aeruginosa and Acinetobacter species.

Main Methods:

  • Simulated 5,000 subjects with meropenem regimens (500 mg every 6, 8, 12 h; 1000 mg every 8, 12 h).
  • Extrapolated pharmacokinetic data from CVVH literature.
  • Utilized 2003 US MYSTIC study MIC data for target attainment calculations.

Main Results:

  • Regimens of 1000 mg every 8 h and 500 mg every 6 h achieved 100% target attainment at the breakpoint.
  • 1000 mg every 8 h demonstrated superior target attainment against resistant P. aeruginosa and Acinetobacter.
  • Higher peak concentrations with 1000 mg every 8 h provided the greatest probability of bactericidal exposure.

Conclusions:

  • Meropenem 1000 mg every 8 h is the optimal regimen for patients on CVVH.
  • Lower doses or extended intervals are not recommended for this patient population.
  • This regimen optimizes the pharmacodynamic profile for effective antimicrobial therapy.

Related Concept Videos

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
Estimation of k and VD of Aminoglycosides01:20

Estimation of k and VD of Aminoglycosides

Aminoglycosides are a class of antibiotics used to treat various bacterial infections. Clinicians must determine the elimination rate constant (k) and volume of distribution (VD) to optimize therapeutic efficacy and minimize toxicity. The k value represents the rate at which the drug is removed from the body, and the VD reflects the degree to which the drug distributes into body tissues. Accurately estimating these parameters allows healthcare professionals to tailor drug dosing to individual...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy01:26

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in critically...
Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady state,...